Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study

被引:40
|
作者
Estill, Janne [1 ]
Egger, Matthias [1 ]
Blaser, Nello [1 ]
Vizcaya, Luisa Salazar [1 ]
Garone, Daniela [2 ]
Wood, Robin [3 ]
Campbell, Jennifer [4 ]
Hallett, Timothy B. [5 ]
Keiser, Olivia [1 ]
机构
[1] Univ Bern, Inst Social & Prevent Med ISPM, CH-3012 Bern, Switzerland
[2] Medecins Sans Frontieres, Khayelitsha ART Programme, Geneva, Switzerland
[3] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa
[4] Clinton Hlth Access Initiat, Boston, MA USA
[5] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England
基金
美国国家卫生研究院; 瑞士国家科学基金会;
关键词
antiretroviral therapy; cost-effectiveness; mathematical model; sub-Saharan Africa; viral load monitoring; CD4 CELL COUNT; SUB-SAHARAN AFRICA; DRUG-RESISTANCE; SOUTH-AFRICA; STRATEGIES; COHORT; TRANSMISSION; MUTATIONS; PROGRAM; OPTIONS;
D O I
10.1097/QAD.0b013e328360a4e5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Monitoring of HIV viral load in patients on combination antiretroviral therapy (ART) is not generally available in resource-limited settings. We examined the cost-effectiveness of qualitative point-of-care viral load tests (POC-VL) in sub-Saharan Africa. Design: Mathematical model based on longitudinal data from the Gugulethu and Khayelitsha township ART programmes in Cape Town, South Africa. Methods: Cohorts of patients on ART monitored by POC-VL, CD4 cell count or clinically were simulated. Scenario A considered the more accurate detection of treatment failure with POC-VL only, and scenario B also considered the effect on HIV transmission. Scenario C further assumed that the risk of virologic failure is halved with POC-VL due to improved adherence. We estimated the change in costs per quality-adjusted life-year gained (incremental cost-effectiveness ratios, ICERs) of POC-VL compared with CD4 and clinical monitoring. Results: POC-VL tests with detection limits less than 1000 copies/ml increased costs due to unnecessary switches to second-line ART, without improving survival. Assuming POC-VL unit costs between US$5 and US$20 and detection limits between 1000 and 10 000 copies/ml, the ICER of POC-VL was US$4010-US$9230 compared with clinical and US$5960-US$25540 compared with CD4 cell count monitoring. In Scenario B, the corresponding ICERs were US$2450-US$5830 and US$2230-US$10380. In Scenario C, the ICER ranged between US$960 and US$2500 compared with clinical monitoring and between cost-saving and US$2460 compared with CD4 monitoring. Conclusion: The cost-effectiveness of POC-VL for monitoring ART is improved by a higher detection limit, by taking the reduction in new HIV infections into account and assuming that failure of first-line ART is reduced due to targeted adherence counselling. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:1483 / 1492
页数:10
相关论文
共 50 条
  • [31] Plasmonic paper for the detection of renal cancer in point-of-care and resource-limited settings
    Hu, Rong
    Morrissey, Jeremiah
    Tian, Limei
    Wang, Congzhou
    Kharasch, Evan
    Singamaneni, Srikanth
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [32] Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions
    Stevens, Wendy
    Gous, Natasha
    Ford, Nathan
    Scott, Lesley E.
    BMC MEDICINE, 2014, 12
  • [33] The Next Phase for Point-of-Care Testing in Resource-Limited Settings Noncommunicable Disease
    Schroeder, Lee F.
    LaBarre, Paul
    Weigl, Bernhard Hans
    Amukele, Timothy
    POINT OF CARE, 2016, 15 (02): : 93 - 95
  • [34] Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions
    Wendy Stevens
    Natasha Gous
    Nathan Ford
    Lesley E Scott
    BMC Medicine, 12
  • [35] Modelling response to antiretroviral therapy without a genotype as a clinical tool for resource-limited settings
    Larder, B. A.
    Revell, A. D.
    Wang, D.
    Hamers, R.
    Tempelman, H.
    Barth, R.
    Wensing, A. M. J.
    Morrow, C.
    Wood, R.
    DeWolf, F.
    Kaiser, R.
    Pozniak, A.
    Lane, H. C.
    Montaner, J. M.
    ANTIVIRAL THERAPY, 2011, 16 : A42 - A42
  • [36] Point-of-care HIV viral load in pregnant women without prenatal care: a cost-effectiveness analysis
    Avram, Carmen M.
    Greiner, Karen S.
    Tilden, Ellen
    Caughey, Aaron B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 221 (03) : 265.e1 - 265.e9
  • [37] Monitoring HIV Antiretroviral Therapy in Resource-Limited Settings: Time to Avoid Costly Outcomes
    Sawe, Frederick K.
    McIntyre, James A.
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (03) : 463 - 465
  • [38] Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings
    Rutstein, Sarah E.
    Price, Joan T.
    Rosenberg, Nora E.
    Rennie, Stuart M.
    Biddle, Andrea K.
    Miller, William C.
    GLOBAL PUBLIC HEALTH, 2017, 12 (10) : 1269 - 1281
  • [39] The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations
    Hyle, Emily P.
    Jani, Ilesh V.
    Rosettie, Katherine L.
    Wood, Robin
    Osher, Benjamin
    Resch, Stephen
    Pei, Pamela P.
    Maggiore, Paolo
    Freedberg, Kenneth A.
    Peter, Trevor
    Parker, Robert A.
    Walensky, Rochelle P.
    AIDS, 2017, 31 (15) : 2135 - 2145
  • [40] A point-of-care PCR test for HIV-1 detection in resource-limited settings
    Jangam, Sujit R.
    Agarwal, Abhishek K.
    Sur, Kunal
    Kelso, David M.
    BIOSENSORS & BIOELECTRONICS, 2013, 42 : 69 - 75